Navigation Links
Scripps Florida scientists identify critical 'quality control' for cell growth
Date:7/5/2012

JUPITER, FL, July 5, 2012 Scientists from the Florida campus of The Scripps Research Institute have identified a series of intricate biochemical steps that lead to the successful production of proteins, the basic working units of any cell.

The study, which appears in the July 6, 2012 edition of the journal Cell, sheds light on the assembly of a structure called the ribosome, a large and complex protein-producing machine inside all living cells. Ribosomes are the targets of many commercially used antibiotics and represent a promising area of research because of the importance of ribosome assembly and function for cell growth. There are well-established links between defects in ribosome assembly and cancer, making this pathway a potential new target for anti-cancer drugs.

"With important cellular machines like ribosomes, it makes sense that some process exists to make sure things work correctly," said Katrin Karbstein, a Scripps Research associate professor who led the study. "We've shown that such a quality control function exists for ribosomal subunits that use the system to do a test run but don't produce a protein. If the subunits don't pass, there are mechanisms to discard them."

Protein Production Line

As part of the protein-production process called "translation," the ribosome decodes information carried in messenger RNA (mRNA) to produce a proteina chain of amino acids.

To produce mature, functioning ribosomal RNAs (rRNAs), the body first makes precursor rRNAs that can be processed into mature ones. In human cells, this is done in two stagesthe first occurs in the nucleolus, a protein-nucleic acid structure inside the nucleus, and finally in the cytoplasm, the basic cellular stew where protein translation occurs.

In the cytoplasm, these pre-mature ribosomal subunits encounter large pools of mature subunits, messenger RNA, and numerous assembly factors and translation factors that help complete the process.

During the final maturation process, various assembly factors prevent the translation process from acting on the subunits prematurely, which would result in their rapid degradation or in the production of incorrectly assembled proteins, both processes with potentially lethal outcomes for the cell.

Trial Run

While the work of these assembly factors explains how premature translation is blocked, their presence raises another important question, Karbstein saidDoes the conversion of inactive assembly intermediates into mature ribosomes require checkpoints to assure that subunits are functional?

In the study, Karbstein and her colleagues were able to show that during this translation-like cycle the newly made ribosome subunit initially joins with its complementary preexisting subunit to form a much larger complex through the influence of a single translation factor.

This large ribosome complex contains no messenger RNA, which is blocked by assembly factors, and thus produces no protein. Once the major functions of the smaller ribosome subunit have been inspected and approved, another translation factor breaks up the complex and actual protein production occurs.

"What is important here is that the test cycle involves the same translational factors that are involved in normal translation," Karbstein said. "It's the most elegant and efficient way to produce perfect ribosomes."

Interestingly, the study noted, the majority of assembly factors involved in this translation-like test cycle are conserved in creatures ranging from one-celled organisms to humans, suggesting that this evolutionary mechanism is common to all.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scripps Research Institute Scientists Develop Alternative to Gene Therapy
2. Scripps Research Institute announces five-year research collaboration with Bristol-Myers Squibb
3. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
4. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
5. Plastic trash altering ocean habitats, Scripps study shows
6. Scripps Florida scientists identify neurotranmitters that lead to forgetting
7. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
8. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
9. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
10. Scripps Research Institute scientists develop antidote for cocaine overdose
11. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Florida scientists identify critical 'quality control' for cell growth
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... PARSIPPANY, N.J. , Jan. 20, 2017 /PRNewswire/ ... the "Company"), a company that provides clinically useful ... that it has entered into a securities purchase ... aggregate of 855,000 shares of common stock in ... placement, the Company has agreed to sell to ...
(Date:1/21/2017)... 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... Company in North America 2016. ... based on the FDA approval of three innovative ... ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
Breaking Biology Technology: